Pages that link to "Q33737175"

The following pages link to The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma (Q33737175):

Displaying 42 items.

• Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? (Q26777927) (← links)
• Emerging therapies for severe asthma (Q26861260) (← links)
• Treatment of allergic asthma: modulation of Th2 cells and their responses (Q27011823) (← links)
• Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma (Q33830363) (← links)
• Advances in targeting cyclic nucleotide phosphodiesterases (Q34139490) (← links)
• The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β 2-adrenoceptor agonist in preclinical animal species (Q34292566) (← links)
• The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma (Q34491824) (← links)
• Biochanin A, a Phytoestrogenic Isoflavone with Selective Inhibition of Phosphodiesterase 4, Suppresses Ovalbumin‐Induced Airway Hyperresponsiveness (Q34706585) (← links)
• Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets (Q34765802) (← links)
• High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids (Q35135980) (← links)
• Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio (Q35576638) (← links)
• Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia (Q35792013) (← links)
• New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma (Q36252920) (← links)
• Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial (Q36355311) (← links)
• Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells (Q36503797) (← links)
• PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease (Q37831477) (← links)
• Future Forms of Immunotherapy and Immunomodulators in Allergic Disease (Q37870455) (← links)
• Novel bronchodilators for the treatment of chronic obstructive pulmonary disease (Q37891286) (← links)
• Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics (Q37893057) (← links)
• Asthma in children and adolescents: a comprehensive approach to diagnosis and management (Q37970318) (← links)
• Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012). (Q38103909) (← links)
• Asthma: beyond corticosteroid treatment (Q38121086) (← links)
• Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. (Q38187182) (← links)
• PDE inhibitors currently in early clinical trials for the treatment of asthma (Q38215280) (← links)
• Small-molecule anti-inflammatory drug compositions for the treatment of asthma: a patent review (2013 - 2014). (Q38478442) (← links)
• Novel approaches to the management of noneosinophilic asthma (Q38756064) (← links)
• Addressing corticosteroid insensitivity in adults with asthma (Q38930984) (← links)
• Bifunctional Drugs for the Treatment of Respiratory Diseases (Q38992596) (← links)
• Can we find better bronchodilators to relieve asthma symptoms? (Q39532081) (← links)
• Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility (Q42419157) (← links)
• The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. (Q44102880) (← links)
• Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials (Q44206747) (← links)
• Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate (Q46120241) (← links)
• Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice (Q47307725) (← links)
• Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target. (Q47650425) (← links)
• Xanthines and Phosphodiesterase Inhibitors (Q51420049) (← links)
• Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity. (Q55016315) (← links)
• Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases (Q58606499) (← links)
• In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor (Q83128967) (← links)
• The reproducibility of bolus allergen challenges; power calculations for clinical trials (Q85367840) (← links)
• Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases (Q90745484) (← links)
• Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis (Q98464921) (← links)